Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DCTH vs SIBN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 5–4 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: DCTH 6 – 0 SIBN Matrix Metrics: DCTH 5 – 4 SIBN

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over SI-BONE, Inc. (SIBN) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas SIBN carries 38.3/100 (SELL) at $23.29 (N/M Forward P/E, -7.6% operating margin).

  • Composite vs. Pillar Nuance: While SIBN currently prints a higher short-term Unified Composite Score (38.3/100 SELL vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (5–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -7.6% operating margin) and revenue trajectory (+70.7% vs. +14.5% YoY).
  • Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both DCTH (35.9/100 SELL) and SIBN (38.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs SIBN
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96
SIBN NASDAQ
SI-BONE, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$23.29
-0.64% 1D
Market Cap $1.1B
TTM Revenue $221M
Forward P/E N/M
Beta / 30D Vol 0.74β · 77% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 8.0 Fund 30.0 Flow 71.0 Mom 31.4
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 56
RSI-14: 55.6 · SMA20: $22.83 · SMA50: $20.47

6-Pillar Scorecard Institutional Category Breakdown (DCTH 6 – 0 SIBN)

Columns: Metric · DCTH · SIBN
1. Valuation Multiples DCTH
Forward P/E N/M N/M
Trailing P/E 133.6x N/M
PEG Ratio 1.60x N/M
EV / Revenue 6.3x 5.0x
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% +14.5%
Earnings Growth (YoY) +750.0% +0.0%
TTM Revenue (USD) $110M $221M
Market Cap $743.8M $1.1B
3. Profitability & Quality DCTH
Gross Margin 87.6% 79.4%
Operating Margin 5.2% -7.6%
Net Profit Margin 6.0% -6.2%
Return on Equity (ROE) 5.4% -7.7%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M -$4.2M
Cash Flow Margin 18.3% -1.9%
Net Cash / Leverage $53M Net Cash $7.5M Net Debt (0.23x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase BREAKOUT BREAKOUT
Current IV / %ile 109.3% (43rd %ile) 44.5% (14th %ile)
Put/Call OI Skew 0.11x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (5) vs SIBN (4)
Institutional Metric DCTH SIBN Criterion Row Edge
Market Capitalization
Scale
$743.8M $1.1B Larger Scale SIBN
Trailing P/E Ratio
Valuation
133.6x N/M Lower Multiple DCTH
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+70.7% +14.5% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% -7.6% Higher Margin DCTH
Net Profit Margin
Profitability
6.0% -6.2% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
5.4% -7.7% Higher ROE DCTH
52-Week Range Position
Momentum
80% ($8–$23) 82% ($11–$26) Stronger Trend SIBN
Beta / 30D Volatility
Risk Regime
1.63β · 131% Vol 0.74β · 77% Vol Lower Realized Risk SIBN
Unified Institutional Score
Composite Signal
35.9 / 100 (SELL) 38.3 / 100 (SELL) Higher Composite SIBN
Trailing 12M Revenue (USD)
Operating Scale
$110M $221M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% 79.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 6.3x EV/Rev N/M PEG · 5.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) -$4.2M ($7.5M Net Debt (0.23x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +21.43 pp
DCTH: +39.77% · SIBN: +18.34%
3M Horizon SIBN +4.95 pp
DCTH: +16.73% · SIBN: +21.68%
6M Horizon DCTH +19.67 pp
DCTH: +77.46% · SIBN: +57.79%
1Y Horizon DCTH +93.63 pp
DCTH: +128.57% · SIBN: +34.94%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DCTH Revenue SIBN Revenue DCTH Op. Margin SIBN Op. Margin Margin Leader
FY2018 N/A $60M N/A -21.6% SIBN
FY2019 N/A $70M N/A -53.5% SIBN
FY2020 N/A $70M N/A -52.6% SIBN
FY2021 $0M $90M -690.0% -57.3% SIBN
FY2022 $0M $110M -1245.1% -56.0% SIBN
FY2023 $0M $140M -1849.0% -33.8% SIBN
FY2024 $40M $170M -33.4% -21.1% SIBN
FY2025 $90M $200M 0.8% -11.1% DCTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SIBN BREAKOUT
74d in phase · OBV DISTRIBUTION
Current IV 44.5%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIBN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
SIBN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.1B market capitalization and -7.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs SIBN Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over SI-BONE, Inc. (SIBN) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin), whereas SIBN carries 38.3/100 (SELL) at $23.29 (N/M Forward P/E, -7.6% operating margin). Composite vs. Pillar Nuance: While SIBN currently prints a higher short-term Unified Composite Score (38.3/100 SELL vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (5–4 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -7.6% operating margin) and revenue trajectory (+70.7% vs. +14.5% YoY). Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both DCTH (35.9/100 SELL) and SIBN (38.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with SIBN at +14.5% YoY revenue growth and +0.0% YoY earnings growth on $221M TTM revenue (79.4% gross margin, -7.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DCTH cumulative revenue shifted +125.0% while SIBN shifted +233.3%. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SIBN.

DCTH screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas SIBN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 5.0x EV/Revenue (-1.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus SIBN (-7.7% ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, SIBN carries 44.5% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKOUT options structure phase (0.74β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.